WO 2004/005521 PCT/US2003/021159

## CLAIMS

What is claimed is:

5

10

25

1. A plastid transformation vector for a stably transforming a plastid, comprising, as operably-linked components, a first flanking sequence, a DNA sequence coding for an insulin-like growth factor-1 (IGF-1) or, which is capable of expression in said plastid genome, and a second flanking sequence.

- 2. The vector of Claim 1, wherein the DNA sequence coding for the IGF-1 is a synthetic IGF-1 (IGF-1s) and consists of about 60% adenine and thymine nucleotides.
  - 3. The vector of Claim 1 further comprising a regulatory sequence.
- 4. The vector of Claim 3, wherein said regulatory sequence comprises a promoter operative in said plastid genome.
  - 5. The vector of Claim 4, wherein said promoter is 16 sRNA.
- 6. The vector of Claim 3, wherein said regulatory sequence comprises psbA 5' and psbA 3' elements.
  - 7. The vector of Claim3, wherein said regulatory sequences further comprise a 5' UTR capable of providing transcription and translation enhancement of said DNA sequence coding for IGF-1.
- 8. The vector of Claim 3, wherein said regulatory sequences further comprise a 3' untranslated region (UTR) capable of conferring transcript stability to said IGF-1.
  - 9. The vector of Claim 1, wherein said first flanking sequence is trnI, and wherein said second flanking sequence is trnA.
  - 10. The vector of Claim 1, wherein the vector is component for stably intergrating into a plastid genome of a plant, and wherein said first and second flanking DNA sequences are substantially homologous to sequences in a spacer region of said plastid genome, and wherein said first and second flanking sequences are conserved in the plastid genome of said higher plant species.
- 11. The vector of Claim 10, wherein said spacer region is a transcriptionally30 active spacer region.

WO 2004/005521 PCT/US2003/021159

12. The vector of Claim 10, wherein said trnI and trnA provide for homologous recombination to insert an IGF-1 or region of an inverted repeat region of a chloroplast genome.

- 13. The vector of Claim 1, wherein said DNA sequence coding for IGF-1 or a substantially homologous DNA sequence of IGF-1 is located in a single copy region of said plastid genome.
  - 14. The vector of Claim 7, wherein said 5' UTR is a 5' UTR of psbA.
  - 15. The vector of Claim 8, wherein said 3' UTR is a 3' UTR of psbA.
- 16. The vector of Claim 1, further comprising a DNA sequence encoding a selectable marker.
  - 17. The vector of Claim 16, wherein said selectable marker is an antibiotic-free selectable marker.
  - 18. The vector of Claim 17, wherein said antibiotic-free selectable marker is Betaine aldehyde dehydrogenase (BADH).
  - 19. The vector of Claim 16, wherein said DNA sequence encoding is selectable marker encodes an antibiotic resistance selectable marker.

15

20

- 20. The vector of Claim 19, wherein said antibiotic resistance selectable marker is aadA.
- 21. A method for producing IGF-1 comprising:
  integrating the plastid transformation vector of Claim 1 into the plastid
  genome of a plant cell; and

growing said plant cell to thereby express said IFN.

- 22. The method of Claim 21, wherein said IGF-1 is competent to produce an immunogenic response in a mammal.
- 25 23. The method of Claim 22, wherein said immunogenic response is substantially free of negative side effects associated with injected IGF-1.
  - 24. An isolated and purified IGF-1, competent to produce and immunogenic response in a mammal.
- 25. The isolated and purified IGF-1 of Claim 24, wherein said IGF-1 is a synthetic IGF-1 having an adenine and thymine DNA content of about 60%.
  - 26. An orally administerable therapeutic human interferon IGF-1, suitable for oral administration to a mammal.

WO 2004/005521 PCT/US2003/021159

27. A method for variable-expressing IGF-1 comprising:
integrating a plastid transformation vector according to Claim 1 into a plastid genome of a plant cell; and

growing said plant cell to express said IGF-1.

- 28. A plant stably transformed with the transformation vector of Claim 1.
- 29. A progeny of the plant of Claim 28.
- 30. A seed of the plant of Claim 28.

5

15

20

- 31. A part of the plant of Claim 28, comprising a plastid including said DNA sequence coding for therapeutic human interferon IFN.
- 10 32. The plant of Claim 28, wherein said plant is an edible plant suitable for mammal consumption.
  - 33. The plant of Claim 28, wherein said plant further comprises at least one chloroplast transformed with the vector of Claim 1.
  - 34. The plant of Claim 28, wherein said plant further comprises mature leaves transformed with the vector of Claim 1.
    - 35. The plant of Claim 28, wherein said plant further comprises young leaves transformed with the vector of Claim 1.
    - 36. The plant of Claim 28, wherein said plant further comprises old leaves transformed with the vector of Claim 1.
  - 37. The plant of Claim 28, wherein the expression of IGF-1 is at least about 6.0 percent total soluble protein.
  - 38. The plant of Claim 28, wherein said expression of IGF-1 in said edible plant is between about 9.5-32.5% total soluble protein.